Given that each subset of DC has different function and crosstalk abilities it has been implied that the most efficient vaccine would include multiple subsets, however there has yet to be any **data** generated/clinical trials completed to support this theory [139]. Additionally, one of the disadvantages of using autologous DCs in vaccines is that it takes a long time to extract them from a patient's blood, which can be reduced by utilising allogenic DCs [140]. There is currently a clinical trial testing a pDC vaccine generated using pDCs from an allogenic cell line in melanoma patients (NCT01863108).